

Quick Heal Technologies Ltd.

(Formerly Known as Quick Heal Technologies Pvt. Ltd.)
Regd. Office: Marvel Edge, Office No. 7010 C & D,
7th Floor, Viman Nagar, Pune 411014.

Tel: +91 20 66813232 | Email: info@quickheal.com

NEW CIN-L72200MH1995PLC091408

Ref No.: QHTL/Sec/SE/2017-18/79

7th February, 2018

The Manager,
Corporate Services,
BSE Limited,
14th floor, P J Towers, Dalal Street,
Mumbai – 400 001
Ref: Security ID : QUICKHEAL
Security Code: 539678

The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL
Series: EQ

Subject: Result Presentation for the quarter ended Q3FY18

Dear Sir/Madam,

Please find enclosed herewith Result Presentation for the quarter ended Q3FY18, for your records.

Please acknowledge the receipt.

Thanking you,

For Quick Heal Technologies Limited

Raghav Mulay Company Secretary

Encl: As above

Pune Pune 2 Dilling Rechnologies Little Rechno




DISCLAIMER

This presentation and the following discussion may contain "forward looking statements" by Quick Heal Technologies Limited ("Quick Heal" or the "Company") that are not historical in nature. These forward looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives are based on the current beliefs, assumptions, expectations, estimates and projections of the management of Quick Heal about the business, industry and markets in which Quick Heal operates.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond Quick Heal's control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward looking statements.

Such statements are not and should not be construed as a representation of future performance or achievements of Quick Heal. In particular, such statements should not be regarded as a projection of future performance of Quick Heal. It should be noted that the actual performance or achievements of Quick Heal may vary significantly from such statements.


Q3 & 9M FY18 RESULTS HIGHLIGHTS



Q3 & 9M FY18 – REVENUE ANALYSIS


In Rs. Million

Q3 FY18 YoY ANALYSIS



^{*} Based on net revenues before adjusting for sales incentives

9M FY18 YoY ANALYSIS



Q3 & 3M FY18 – LICENSE SELLING PATTERN


Q3 FY18 YoY ANALYSIS

NUMBER OF LICENSES SOLD ('000)

1,345 1,128 241 198 1,104 930 19% Q3 FY17 Q3 FY18 % Share Q3 FY17 Q3 FY18 82.4% 82.1% Retail 17.6% 17.9% ■ Enterprises & Government

9M FY18 YoY ANALYSIS





- Based on net revenues before adjusting for sales incentives
- Increase in retail licenses sold in Q3 FY18.

Q3 & 9M FY18 – COST ANALYSIS


In Rs Million

Head	Consolidated					
neau	Q3 FY18,a	Q2 FY18,a	Q1 FY18,a	Q4 FY17,a	Q3 FY17,a	
Operating Cost						
Salaries	111.3	113.8	116.8	116.5	118.7	
Fees for technical services	19.7	20.7	24.1	24.8	24.9	
Technology subscription charges	4.9	4.3	3.5	14.3	13.6	
R&D Expenses (A)	135.8	138.8	144.4	155.6	157.3	
Salaries	74.1	86.7	91.4	100.6	99.7	
Technical Support Cost	17.6	21.0	20.7	19.4	19.1	
Advertising Expenses	94.9	23.3	32.6	71.4	44.2	
Sales Promotion	36.8	8.2	22.7	3.4	12.6	
Traveling and conveyance	7.2	6.8	6.7	11.6	13.5	
Selling & Marketing Expenses (B)	230.5	145.9	174.1	206.4	189.0	
Salaries	47.1	50.8	48.9	43.7	45.7	
Other Expenses	78.8	69.5	78.2	90.5	73.3	
G&D (C)	125.9	120.3	127.1	134.2	119.0	
Total Expenditure (A+B+C)	492.3	404.9	445.6	496.2	465.3	

Q3 & 9M FY18 - WORKING CAPITAL ANALYSIS

ADOPTION OF EFFICIENT SALES & CREDIT MECHANISM LEADING TO IMPROVEMENT IN WORKING CAPITAL CYCLE

- Increased handholding between sales team and dealer-retailer network to ensure faster sales.
- Realignment of dealer incentives to ensure timely sales as well as stock clearance throughout the supply chain.



Note: Net Working Capital Days = [(Net Working Capital / Third Quarter Sales) * (91 days)]

Calculation is based on net revenues before adjusting for sales incentives



Q3 & 9M FY18 CONSOLIDATED RESULTS – PROFIT & LOSS

In Rs Million

Head		Consolidated Consolidated						
Heau	Q3 FY18,a	Q3 FY17,a	Growth	% Change	9M FY18,a	9M FY17,a	Growth	% Change
Revenue	642.4	545.5	96.9	17.8%	1,996.2	2,088.9	-92.7	-4.4%
Direct Cost	35.5	48.5	13.0	26.8%	104.4	181.3	76.8	42.4%
Gross profit	607.0	497.1	109.9	22.1%	1,891.8	1,907.6	-15.9	-0.8%
Gross Margin, %	94.5%	91.1%			94.8%	91.3%		
Operating Costs								
R&D Cost	135.8	157.3	21.4	13.6%	419.0	479.9	60.9	12.7%
Sales and Marketing (S&M)	230.5	189.0	-41.5	-22.0%	550.6	521.7	-28.9	-5.5%
General Administration (G&A)	125.9	119.0	-7.0	-5.8%	373.3	370.5	-2.8	-0.8%
Total	492.3	465.3	-27.0	-5.8%	1,342.9	1,372.0	29.1	2.1%
EBIDTA	114.7	31.8	82.9	260.8%	548.9	535.6	13.3	2.5%
Depreciation / Amortization	68.2	75.9	7.7	10.1%	200.0	227.6	27.5	12.1%
EBIT	46.5	-44.1	90.6	-205.3%	348.9	308.1	40.8	13.3%
Other Income	52.2	76.8	-24.6	-32.0%	164.9	222.3	-57.4	-25.8%
Profit Before Tax & Exceptional Item	98.7	32.7	66.0	201.8%	513.8	530.3	-16.6	-3.1%
Exceptional Item	-	-	-	0.0%	-	37.8	37.8	100.0%
Tax	32.2	16.5	-15.7	-95.4%	175.5	182.3	6.7	3.7%
Profit After Tax	66.5	16.2	50.3	309.9%	338.2	310.3	27.9	9.0%
	Recond	iliation betw	een IGA	AP and IND-A	AS			
Reveune (Gross)	801.8	647.7	154.1	23.8%	2,506.7	2,485.8	21.0	0.8%
Taxes	129.2	50.4	-78.8	-156.4%	371.4	189.0	-182.4	-96.5%
Net revenue as per IGAAP	672.6	597.3	75.3	12.6%	2,135.3	2,296.8	-161.4	-7.0%
Less: Dealer Incentive	30.2	51.7	21.6	41.7%	139.1	207.8	68.7	33.1%
Net revenue after Dealer Incentive	642.4	545.5	96.9	17.8%	1,996.2	2,088.9	-92.7	-4.4%

Quick Heal

NOTE: Certain figures have been re-grouped wherever necessary

Q3 & 9M FY18 CONSOLIDATED RESULTS - RATIO ANALYSIS

Ratio Analysis

Llood.	Consolidated					
Head Head	Q3 FY18,a	Q3 FY17,a	9M FY18,a	9M FY17,a		
Expenses						
Direct Cost / Revenue	5.5%	8.9%	5.2%	8.7%		
R&D / Revenue	21.1%	28.8%	21.0%	23.0%		
S&M / Revenue	35.9%	34.7%	27.6%	25.0%		
G&A / Revenue	19.6%	21.8%	18.7%	17.7%		
Total Cost / Revenue	76.6%	85.3%	67.3%	65.7%		
Margin						
Gross Margin	94.5%	91.1%	94.8%	91.3%		
EBIDTA	17.8%	5.8%	27.5%	25.6%		
EBIT	7.2%	-8.1%	17.5%	14.7%		
PBT	15.4%	6.0%	25.7%	25.4%		
PAT	10.4%	3.0%	16.9%	14.9%		

DECEMBER 31, 2017 CONSOLIDATED BALANCE SHEET

Particulars (In Rs Mn)	Dec-17	Dec-16	Particulars (In Rs Mn)	Dec-17	Dec-16
			Non-Current Assets:		
Share Holder's Funds:			Property, plant and equipment	1,656.6	1,850.8
Equity Share Capital	703.2	700.9	Capital work-in-progress	137.1	126.3
			Other Intangible assets	43.6	74.6
Share application money pending allotment	-	0.1	Non-current financial assets		
Reserves And Surplus	6,068.0	5,693.2	Investments	66.7	36.5
Total Shareholder Funds	6,771.2	6,394.2	Loan and Security Deposits	3.3	0.2
			Bank Balances	3.5	1.3
Non-Current Liabilities			Deferred tax assets (net)	65.2	83.8
Net employee defined benefit liabilities	25.4	24.2	Non-current tax assets (net)	300.8	206.3
			Other non-current assets	83.1	3.0
Current Liabilities:			Total Non-Current Assets	2,359.8	2,382.8
Trade and Other Payables	383.2	329.9	Current assets:		
			Inventories	55.1	66.3
Other Financial Libilities	9.8	8.1	Investment in Mutual Fund	2,807.7	1,306.1
			Trade and other receivables	524.4	815.8
Other Libilities	96.0	129.2	Bank Balances & Cash and Cash Equivalents	104.5	179.8
			Investment in Fixed Deposit	1,514.2	2,046.1
Net employee defined benefit liabilities	13.7	12.9	Loans and Security Deposits	8.8	9.6
Current Tax Liabilities (Net)	214.2	62.0	Interest accured	50.5	102.4
			Other Current assets	88.7	51.5
Total Current Liabilities	717.0	542.0	Total Current Assets	5,153.8	4,577.5
Total Equity & Liabilities	7,513.6	6,960.5	Total Assets	7,513.6	6,960.5

Q3 & 9M FY18 STANDALONE RESULTS – PROFIT & LOSS

In Rs Million

Head Head	Q3 FY18,a	Q3 FY17,a	Growth	% Change	9M FY18,a	OM EVAZ -	0	0/ 01
		40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Glowth	% Change	9W F 118,a	9M FY17,a	Growth '	% Change
Revenue	635.9	542.8	93.1	17.2%	1,978.4	2,082.2	-103.8	-5.0%
Direct Cost	31.5	46.0	14.5	31.5%	100.6	171.0	70.4	41.2%
Gross profit	604.4	496.8	107.6	21.7%	1,877.9	1,911.2	-33.4	-1.7%
Gross Margin, %	95.0%	91.5%			94.9%	91.8%		
Operating Costs								
R&D Cost	135.8	157.3	21.4	13.6%	419.0	479.9	60.9	12.7%
Sales and Marketing (S&M)	220.6	175.0	-45.6	-26.1%	527.1	481.6	-45.5	-9.4%
General Administration (G&A)	116.8	115.7	-1.1	-0.9%	355.6	360.0	4.5	1.2%
Total	473.2	447.9	-25.3	-5.6%	1,301.6	1,321.5	19.9	1.5%
EBIDTA	131.2	48.8	82.3	168.6%	576.2	589.7	-13.5	-2.3%
Depreciation / Amortization	67.9	75.6	7.7	10.2%	199.7	227.1	27.4	12.1%
EBIT	63.3	-26.8	90.0	-336.2%	376.5	362.7	13.9	3.8%
Other Income	51.7	75.7	-24.0	-31.7%	163.3	218.9	-55.6	-25.4%
Profit Before Tax & Exceptional Item	115.0	48.9	66.1	135.1%	539.8	581.6	-41.7	-7.2%
Exceptional Item	3.3	6.3	-3.0	-48.2%	3.3	44.1	40.9	92.6%
Tax	32.0	16.4	-15.6	-94.7%	175.0	182.1	7.1	3.9%
Profit After Tax	79.7	26.1	53.5	204.8%	361.6	355.4	6.2	1.7%
	Recon	ciliation betw	een I GAAP	and IND-AS				
Reveune (Gross)	794.2	644.9	149.4	23.2%	2,488.0	2,479.1	8.9	0.4%
Taxes	129.2	50.4	-78.8	-156.4%	371.4	189.0	-182.4	-96.5%
Net revenue as per IGAAP	665.1	594.5	70.6	11.9%	2,116.6	2,290.0	191.3	8.4%
Less: Dealer Incentive	29.2	51.7	22.6	43.6%	138.1	207.8	69.7	33.5%
Net revenue after Dealer Incentive	635.9	542.8	93.1	17.2%	1,978.4	2,082.2	-103.8	-5.0%

Standalone

Q3 & 9M FY18 STANDALONE RESULTS – RATIO ANALYSIS


Ratio Analysis

Head	Standalone						
neau	Q3 FY18,a	Q3 FY17,a	9M FY18,a	9M FY17,a			
Expenses							
Direct Cost / Revenue	5.0%	8.5%	5.1%	8.2%			
R&D / Revenue	21.4%	29.0%	21.2%	23.0%			
S&M / Revenue	34.7%	32.2%	26.6%	23.1%			
G&A / Revenue	18.4%	21.3%	18.0%	17.3%			
Total Cost / Revenue	74.4%	82.5%	65.8%	63.5%			
Margin							
Gross Margin	95.0%	91.5%	94.9%	91.8%			
EBIDTA	20.6%	9.0%	29.1%	28.3%			
EBIT	9.9%	-4.9%	19.0%	17.4%			
PBT	18.1%	9.0%	27.3%	27.9%			
PAT	12.5%	4.8%	18.3%	17.1%			

DECEMBER 31, 2017 STANDALONE BALANCE SHEET

Particulars (In Rs Mn)	Dec-17	Dec-16	Particulars (In Rs Mn)	Dec-17	Dec-16
			Non-Current Assets:		
Share Holder's Funds:			Property, plant and equipment	1,655.5	1,848.7
Equity Share Capital	703.2	700.9	Capital work-in-progress	137.1	126.2
			Other Intangible assets	43.3	74.6
Share application money pending allotment	-	0.1	Non-current financial assets		
Reserves And Surplus	6,266.8	5,847.8	Investments	335.0	325.8
Total Shareholder Funds	6,970.0	6,548.8	Loan and Security Deposits	3.2	-
			Bank Balances	3.6	1.2
Non-Current Liabilities			Deferred tax assets (net)	65.1	83.8
Net employee defined benefit liabilities	25.4	22.4	Non-current tax assets (net)	300.8	206.4
			Other non-current assets	82.9	15.5
Current Liabilities:			Total Non-Current Assets	2,626.6	2,682.3
Trade and Other Payables	378.0	350.3	Current assets:		
			Inventories	47.9	59.5
Other Financial Libilities	12.6	13.0	Investment in Mutual Fund	2,807.7	1,306.1
			Trade and other receivables	513.9	822.1
Other Libilities	94.3	120.4	Investment in Fixed Deposit	1,514.2	2,046.5
			Bank Balances & Cash and Cash Equivalents	51.1	68.0
Net employee defined benefit liabilities	13.7	14.6	Loans and Security Deposits	8.4	8.6
Current Tax Liabilities (Net)	213.6	62.2	Interest accured	50.5	85.3
			Other Current assets	87.4	53.4
Total Current Liabilities	712.2	560.5	Total Current Assets	5,080.9	4,449.5
Total Equity & Liabilities	7,707.5	7,131.7	Total Assets	7,707.5	7,131.7

SHAREHOLDING STRUCTURE



FOR FURTHER QUERIES

Quick Heal

Security Simplified

Mr. Rajesh Ghonasgi

Quick Heal Technologies Limited Chief Financial Officer

Email ID: rajesh.ghonasgi@quickheal.co.in

Contact No: +91 (20) 6681 3232

Mr. Raghav Mulay

Quick Heal Technologies Limited Company Secretary

Email ID: cs@quickheal.co.in

Contact No: +91 (20) 6681 3232